| Literature DB >> 24409150 |
Nicola Ferrara1, Klara Komici2, Graziamaria Corbi3, Gennaro Pagano2, Giuseppe Furgi4, Carlo Rengo1, Grazia D Femminella2, Dario Leosco2, Domenico Bonaduce2.
Abstract
Elderly healthy individuals have a reduced exercise tolerance and a decreased left ventricle inotropic reserve related to increased vascular afterload, arterial-ventricular load mismatching, physical deconditioning and impaired autonomic regulation (the so called "β-adrenergic desensitization"). Adrenergic responsiveness is altered with aging and the age-related changes are limited to the β-adrenergic receptor density reduction and to the β-adrenoceptor-G-protein(s)-adenylyl cyclase system abnormalities, while the type and level of abnormalities change with species and tissues. Epidemiological studies have shown an high incidence and prevalence of heart failure in the elderly and a great body of evidence correlate the changes of β-adrenergic system with heart failure pathogenesis. In particular it is well known that: (a) levels of cathecolamines are directly correlated with mortality and functional status in heart failure, (b) β1-adrenergic receptor subtype is down-regulated in heart failure, (c) heart failure-dependent cardiac adrenergic responsiveness reduction is related to changes in G proteins activity. In this review we focus on the cardiovascular β-adrenergic changes involvement in the aging process and on similarities and differences between aging heart and heart failure.Entities:
Keywords: G-protein coupled receptor kinase; aging heart; exercise; failing heart; β-adrenergic receptors; β-adrenoceptor desensitization; β-adrenoceptor down-regulation
Year: 2014 PMID: 24409150 PMCID: PMC3885807 DOI: 10.3389/fphys.2013.00396
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
Cardiovascular system: the main general age-related changes in β-adrenergic signaling.
| Abrass and Scapace, | β-AR density | Human (circulating lymphocytes) | Unchanged |
| Landmann et al., | β-AR density | Human (circulating lymphocytes) | Unchanged |
| Gudmundsdottir et al., | β-AR density | Rat (heart) | Decreased |
| Bohm et al., | β-AR density | Rat (heart) | Unchanged |
| Bohm et al., | G | Rat (heart) | Increased |
| White et al., | β1-AR density | Human (heart) | Decreased |
| Bazan et al., | β-AR density | Rat (heart) | Unchanged |
| Cerbai et al., | β-AR density | Rat (heart) | Decreased |
| Ferrara et al., | β-AR density | Guinea-pig (heart) | Decreased |
| Ferrara et al., | G | Guinea-pig (heart) | Unchanged |
| Ferrara et al., | G | Giunea-pig (heart) | Increased |
| Xiao et al., | β1, 2-AR density | Rat (heart) | Decreased |
| Xiao et al., | G | Rat (heart) | Unchanged |
| Schutzer et al., | β-AR | Rat (aorta) | Decreased |
| Schutzer et al., | GRK2, GRK3, β-arrestin | Rat (aorta) | Increased |
| Leinweber et al., | GRK | Human (heart) | Unchanged |
Failing heart: the main general changes in β-adrenergic signaling.
| Bristow et al., | β-AR density | Human (heart) | Decreased |
| Bristow et al., | β1-AR density | Human (heart) | Decreased |
| Brodde et al., | β1, 2-AR density | Human (heart | Decreased |
| Feldman et al., | α G40 activity | Human (heart) | Increased |
| Ungerer et al., | β-ARK | Human (heart) | Up-regulated |
| Fu et al., | G | Human (heart) | Increased |
| Ping et al., | β-AR | Human (heart) | Down-regulated |
| Ping et al., | AC | Human (heart) | Down-regulated |
| Ping et al., | GRKs | Human (heart) | Increased |
| Rockman et al., | β-ARK1 Inhibitors (overexpression) | Transgenic mouse (heart) | Increased contractility |
| Harding et al., | β-ARKct (overexpression) | Transgenic mouse (heart) | Increased contractility |
| Vinge et al., | β-ARRESTIN1 | Rat (heart) | Increased |
| Vinge et al., | GRK2 | Rat (heart) | Increased |
| Vinge et al., | GRK5 | Rat (heart) | Increased |
| Iaccarino et al., | GRK2 | Human (heart) | Up-regulated |
| Lymperopoulos et al., | α2-AR | Rat (adrenal medulla) | Down-regulated |
| Lymperopoulos et al., | α2-AR | Transgenic mouse (adrenal medulla) | Down-regulated |
| Lymperopoulos et al., | GRK2 | Rat (adrenal medulla) | Up-regulated |
| Lymperopoulos et al., | GRK2 | Transgenic mouse (adrenal medulla) | Up-regulated |
| Rengo et al., | α2-AR density | Rat (adrenal medulla) | Down-regulated |
| Rengo et al., | GRK2 | Rat (adrenal medulla) | Increased |
| Rengo et al., | GRK2 | Human (lymphocytes) | Increase |